A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
2006/08/01 by Carlos A. Zarate, Jaskaran Singh, Jaskaran B. Singh +7 · 51 citations
Medicine · Neuroscience · #Treatment of Major Depression #Neurotransmitter Receptor Influence on Behavior #Tryptophan and brain disorders
paper · pdf · doi:10.1001/archpsyc.63.8.856
Abstract
CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders. OBJECTIVE: To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression. DESIGN: A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005. SETTING: Mood Disorders Research Unit at the National Institute of Mental Health. Patients Eighteen subjects with DSM-IV major depression (treatment resistant). INTERVENTIONS: After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion. Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale. RESULTS: Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week. CONCLUSIONS: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.
Cited by
- Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus
- Similar destabilization of neural dynamics under different general anesthetics
- Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior
- Ketamine and Esketamine in Clinical Trials: <scp>FDA‐</scp>Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations
- The combination of plasma glutamate and physical impairment after acute stroke as a potential indicator for the early-onset post-stroke depression
- Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression
- Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
- Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
- (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression
- Ketamine: Mechanisms and Relevance to Treatment of Depression
- Is Forced Swimming Immobility a Good Endpoint for Modeling Negative Symptoms of Schizophrenia? - Study of Sub-Anesthetic Ketamine Repeated Administration Effects
- Similar destabilization of neural dynamics under different general anesthetics
- Ketamine reduces the neural distinction between self- and other-produced affective touch: a randomized double-blind placebo-controlled study
- Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
- Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
- Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
- Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
- Targeting inflammation: a potential approach for the treatment of depression
- Responding to medicinal and non‐medicinal ketamine use
- Ketamine Treatment and Global Brain Connectivity in Major Depression
- Inhibition of microglial glutaminase alleviates chronic stress-induced neurobehavioral and cognitive deficits
- Randomized trial of ketamine masked by surgical anesthesia in patients with depression
- Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
- From Brain to Behavior: Mechanistic and Therapeutic Insights into Mood and Anxiety Disorders
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. [europepmc]
- The molecular neurobiology of depression. [europepmc]
- A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. [europepmc]
- Glutamate receptor ion channels: structure, regulation, and function. [europepmc]
- mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. [europepmc]
- Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. [europepmc]
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. [europepmc]
- Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. [europepmc]
- Major depressive disorder: new clinical, neurobiological, and treatment perspectives. [europepmc]
- Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. [europepmc]
- Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. [europepmc]
- Synaptic dysfunction in depression: potential therapeutic targets. [europepmc]
- Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. [europepmc]
- The neurology of mTOR. [europepmc]
- Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. [europepmc]
- BDNF - a key transducer of antidepressant effects. [europepmc]
- Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. [europepmc]
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites. [europepmc]
- Mechanisms of ketamine action as an antidepressant. [europepmc]
- Psychedelics Promote Structural and Functional Neural Plasticity. [europepmc]
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. [europepmc]
- Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. [europepmc]
- Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. [europepmc]
- Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. [europepmc]
- Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels. [europepmc]
Related